Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

12.590
+0.0700.56%
Volume:1.48M
Turnover:18.40M
Market Cap:12.49B
PE:-37.50
High:12.700
Open:12.500
Low:12.120
Close:12.520
52wk High:18.750
52wk Low:2.820
Shares:992.00M
HK Float Shares:992.00M
Volume Ratio:0.57
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.336
ROE:-12.77%
ROA:-12.32%
PB:5.98
PE(LYR):-37.50
PS:4728.22

Loading ...

Hong Kong Stock Buyback Summary | November 3

Stock News
·
Nov 03, 2025

Assessing Ascletis Pharma (SEHK:1672) Valuation Following ASC36 Obesity Pipeline Advancement

Simply Wall St.
·
Nov 03, 2025

Ascletis Pharma (SEHK:1672) Advances AI-Discovered Obesity Drug ASC36 Is Innovation Accelerating Competitive Positioning?

Simply Wall St.
·
Nov 01, 2025

Ascletis Pharma (01672) Announces Share Repurchase and Updated Share Figures

Bulletin Express
·
Oct 31, 2025

ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$1.93 Million on October 31

Stock News
·
Oct 31, 2025

Ascletis Pharma Files HKEX Disclosure on Repurchase of 200,000 Shares at HKD 1,932,670

Reuters
·
Oct 31, 2025

HK Movers|Biotech Shares Soar. 3SBIO up 11%; RemeGen up 8%; SKB BIO up 7%; Junshi Bio up 5%; Hengrui Pharma and Innocare up 4%.

Tiger Newspress
·
Oct 31, 2025

Hong Kong Stocks Movement | ASCLETIS-B (01672) Rises Over 4% as Subcutaneous Amylin Receptor Agonist ASC36 Enters Clinical Development

Stock News
·
Oct 31, 2025

Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies

Reuters
·
Oct 30, 2025

ASCLETIS-B (01672) Selects Best-in-Class Monthly Subcutaneous Amylin Receptor Agonist ASC36 for Clinical Development

Stock News
·
Oct 30, 2025

Ascletis Pharma Inc. (1672) Announces Once-Monthly Amylin Receptor Agonist ASC36 for Clinical Development

Bulletin Express
·
Oct 30, 2025

HK Stock Buyback Summary | October 29

Stock News
·
Oct 29, 2025

Ascletis Pharma (01672) Announces Update on Share Repurchase and Treasury Share Changes

Bulletin Express
·
Oct 28, 2025

ASCLETIS-B (01672) Repurchased 100,000 Shares for HK$918,900 on October 28

Stock News
·
Oct 28, 2025

Ascletis Pharma Repurchases 100,000 Shares for HKD 918,910 in HKEX Disclosure

Reuters
·
Oct 28, 2025

Ascletis Pharma to Present Obesity Drug Study Findings at Georgia Conference

MT Newswires Live
·
Oct 27, 2025

Ascletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares

Bulletin Express
·
Oct 27, 2025

Ascletis (1672) Announces Multiple Presentations on Obesity Pipeline at ObesityWeek® 2025

Bulletin Express
·
Oct 27, 2025

ASCLETIS-B (01672): ASCLETIS to Present Research Findings on ASC30 Oral Tablets, ASC30 Injection, and ASC31 Combined with ASC47 at ObesityWeek® 2025

Stock News
·
Oct 27, 2025

Assessing Ascletis Pharma (SEHK:1672) Valuation After Strong Share Price Surge

Simply Wall St.
·
Oct 25, 2025